Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Operations (2019 - 2025)

Benitec Biopharma's Cash from Operations history spans 7 years, with the latest figure at 12300000.0 for Q1 2025.

  • For Q1 2025, Cash from Operations rose 298.07% year-over-year to 12300000.0; the TTM value through Mar 2025 reached 3290000.0, up 83.72%, while the annual FY2024 figure was 19400000.0, 7.71% down from the prior year.
  • Cash from Operations for Q1 2025 was 12300000.0 at Benitec Biopharma, up from 7714000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12300000.0 in Q1 2025 and bottomed at 7714000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 4300000.0 (2021), against an average of 3555470.59.
  • The largest annual shift saw Cash from Operations tumbled 156.83% in 2021 before it soared 298.07% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 3300000.0 in 2021, then tumbled by 77.42% to 5855000.0 in 2022, then rose by 9.09% to 5323000.0 in 2023, then plummeted by 44.92% to 7714000.0 in 2024, then skyrocketed by 259.45% to 12300000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Cash from Operations are 12300000.0 (Q1 2025), 7714000.0 (Q4 2024), and 4586000.0 (Q3 2024).